News-Medical.Net on MSN21h
Mount Sinai-led research uncovers mechanisms behind Crohn's disease inflammationA research team led by Mount Sinai has uncovered mechanisms of abnormal immune cell function that may lead to Crohn's disease ...
Crohn's disease belongs to a group of conditions known as inflammatory bowel diseases (IBD). This chronic condition causes ...
A research team led by Mount Sinai has uncovered mechanisms of abnormal immune cell function that may lead to Crohn's disease ...
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has announced that the U.S. Food and Drug Administration (FDA) has approved ...
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
Pharmaceutical Technology on MSN2d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s diseaseJ&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in ...
New study shows that dysfunction of protective immune cells in GI tract may contribute to onset of inflammation in Crohn's disease.
The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
In patients with Crohn's disease and intermediate to high preoperative corticosteroid use, primary ileocaecal resection leads ...
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...
Crohn’s disease is an autoimmune disease and a type of inflammatory bowel disease (IBD). If you have one autoimmune disease, like Crohn’s, you are more likely to have another autoimmune disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback